RAPS: FDA Withdraws Document Calling on Biosimilar Developers to Submit 10 Random Suffixes

The US Food and Drug Administration (FDA) on Tuesday withdrew a document submitted to the Office of Management and Budget (OMB) that offered new details on how biosimilar developers would submit an ordered list of 10 random suffixes as part of the naming process for biologics and biosimilars.